Facilitated By

San Antonio Medical Foundation

A Randomized, Controlled, Open-Label, Phase 3 Study Of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone For Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory To Lenalidomide

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
HJF
Research Start Date
Status
Active

The primary objective of this study is to compare the PFS ofmelflufen plus dexamethasone (Arm A) versus pomalidomide plus dexamethasone (Arm B) as assessed by the Independent Review Committee (!RC) according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC).

Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.